Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    Risk of TB Higher for Patients Taking Infliximab, Adalimumab, Than Etanercept - (DGNews)
    Golimumab Effective in Patients With RA Who Have Poor Response to Other Drugs - (DGNews)
    TopAbstracts in Rheumatoid Arthritis 06/25/2009 - (DGNews)
    Initial Therapy With Adalimumab Plus Methotrexate Leads to Better Outcomes Over 5 Years in Patients With Early Rheumatoid Arthritis: Presented at EULAR - (DGDispatch)
    Abatacept Plus Methotrexate Safe, Effective for Up to 5 Years in Patients With Rheumatoid Arthritis: Presented at EULAR - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
    • Benefits of Early, Aggressive, and Appropriate Intervention in Rheumatoid Arthritis
    • Safety of Novel Immunomodulatory Therapies
      Rheumatoid Arthritis: The Heart of the Matter Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis
      New Recommendations for Disease-Modifying Antirheumatic Drugs and Emerging Options for the Treatment of Rheumatoid Arthritis
      Failing a TNF Inhibitor: What About Switching?

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Patient with Hepatitis B and Rheumatoid Arthritis
        Autologous Chondrocyte Implantation for Rheumatoid Arthritis of the Knee: A Case Report
        Complete Heart Block and Severe Aortic Stenosis in a Patient with Rheumatoid Arthtritis: A Case Report
        Limited Wegener's Granulomatosis Presenting as Lung Nodules in a Patient with Rheumatoid Arthritis: A Case Report
        Aseptic Meningitis in a Patient Taking Etanercept for Rheumatoid Arthritis: A Case Report

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Adalimumab Plus Methotrexate May Improve the Health-Related Quality of Life for Patients with Rheumatoid Arthritis

        A DGReview of :"Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate"
        Rheumatology

        04/08/2004
        By Jillian Lokere


        Treatment with adalimumab, a human monoclonal antibody against tumour necrosis factor, plus methotrexate appears to improve the health-related quality of life for patients with rheumatoid arthritis (RA), new research suggests.

        The autoimmune disease RA has a negative impact upon patients' health-related quality of life (HRQoL) because of the hallmark joint inflammation and erosive damage of articular cartilage and bone. Clinical trials have shown that a combination therapy of adalimumab plus methotrexate (MTX) is safe and significantly improves clinical disease response. However, the effect of adalimumab plus methotrexate on HRQoL had not been studied.

        George Torrance, PhD, with Innovus Research, Burlington, Ontario, Canada, and colleagues analysed the data from 2 randomised, double-blind, placebo-controlled clinical trials of adalimumab plus MTX to extract information about this treatment's effect on HRQoL.

        The first study, ARMADA, is a 24-week trial of 271 patients with RA who had active disease while on MTX. The second study, DE019, is a 52-week trial of 619 patients with RA. Only data from the placebo or adalimumab 40 mg every other week (eow) groups were analysed. At various time points during each study, patients were asked to fill out the most recent version of the well-established Health Utilities Index (HUI13), which measures vision, hearing, speech, ambulation, dexterity, emotion, cognition and pain.

        HUI13 attribute scores over the time points were converted into a health utility curve. Area under the curve analysis was used to determine HRQoL changes for each patient, with the units of measure being quality-adjusted life years (QALYs).

        Mean overall HUI3 scores at baseline were 0.38 for ARMADA and 0.44 for DE019 (trial-adjusted population norm HUI3 scores = 0.88). Patients treated with adalimumab 40 mg eow had improved HU13 scores as compared with the placebo group (0.22 vs. 0.04 in ARMADA and 0.21 vs. 0.07 in DE019). When HRQoL changes were calculated, the adalimumab treatment produced 0.145 QALYs gained per year in ARMADA and 0.104 QALYs gained per year in DE019 trials (P < .0001 for both).

        "These results provide strong evidence that adalimumab, at the approved dose of 40 mg eow, plus methotrexate, achieves clinically important and statistically significant improvements in health utility," conclude Dr. Torrance and colleagues.

        Rheumatology 2004 March 23;[epub ahead of print]. "Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send